Insider Stock Trading History of Equels Thomas K.


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Equels Thomas K. since year 2005. The trader's CIK number is 1450324. At the time of this reporting, Equels Thomas K. is the CEO, President of Hemispherx Biopharma Inc . (stock ticker symbol HEB). See this page for all insider trading activities at Hemispherx Biopharma Inc .


Stock purchases, sales, and option exercises reported by insider Equels Thomas K. since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-04-27 HEB Hemispherx Biopharma Inc Buy 72,464 .69 50,000
2017-04-11 HEB Hemispherx Biopharma Inc Buy 200,000 .50 100,000
2016-12-22 HEB Hemispherx Biopharma Inc Buy 68,493 .73 49,999
2016-11-01 HEB Hemispherx Biopharma Inc Buy 10,000 1.00 10,000
2016-07-08 HEB Hemispherx Biopharma Inc Buy 48,000 .12 5,664
2016-06-29 HEB Hemispherx Biopharma Inc Buy 59,000 .12 7,080
2016-06-30 HEB Hemispherx Biopharma Inc Buy 56,000 .12 6,720
2016-07-01 HEB Hemispherx Biopharma Inc Buy 56,000 .12 6,664
2016-03-18 HEB Hemispherx Biopharma Inc Buy 30,000 .13 3,960
2016-03-11 HEB Hemispherx Biopharma Inc Buy 40,000 .16 6,360
2016-03-10 HEB Hemispherx Biopharma Inc Buy 30,000 .16 4,890
2015-08-13 HEB Hemispherx Biopharma Inc Buy 29,104 .18 5,238
2015-08-14 HEB Hemispherx Biopharma Inc Buy 50,000 .18 9,000
2015-04-27 HEB Hemispherx Biopharma Inc Buy 100,000 .24 24,400
2015-04-20 HEB Hemispherx Biopharma Inc Buy 100,000 .24 23,900
2015-04-15 HEB Hemispherx Biopharma Inc Buy 100,000 .23 22,500

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Equels Thomas K. (CEO, President of Hemispherx Biopharma Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.